Video

Immunotherapy revolutionizes frontline treatment in advanced RCC

Author(s):

Urology Times staff

Michael E. Hurwitz, MD, PhD, an associate professor of Internal Medicine at the Yale Cancer Center, discusses how immune checkpoint inhibitor–based combination have dramatically altered the frontline treatment paradigm for patients with advanced renal cell carcinoma.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!
Related Videos
Doctor consulting patient | Image Credit: © Liudmila Dutko - stock.adobe.com
Female doctor typing on her laptop computer in medical office | Image Credit: © Rostislav Sedlacek - stock.adobe.com
Rebecca A. Campbell, MD, answers a question during a Zoom video interview
Betty Wang, MD, discusses studies from the 2025 EAU meeting
Related Content
What urologists can expect in Q3 of 2025
June 30th 2025

What urologists can expect in Q3 of 2025

Benjamin P. Saylor Hannah Clarke
A comprehensive guide to the key regulatory decisions and conferences slated for Q3 of 2025.
female doctor talking with male patient
December 22nd 2022

Dr. Katherine Rotker on destigmatizing sexual health

Urology Times staff
"I think there's a lot of fear that can go into talking about these topics," says Katherine Rotker, MD.
Human kidney cross section on scientific background | Image Credit: © Crystal light - stock.adobe.com
June 5th 2025

Sintilimab plus fruquintinib under review in China for advanced renal cell carcinoma

Hannah Clarke
The new drug application is backed by data from the phase 2/3 FRUSICA-2 trial.
Jad Chahoud, MD, MPH
June 5th 2025

Zanzalintinib plus nivolumab shows safety, efficacy for stage 4 RCC

Benjamin P. Saylor
ORR in the zanzalintinib plus nivolumab arm was 63% (95% CI: 46-77) vs 40% (95% CI: 25-57) in the zanzalintinib plus nivolumab/relatlimab arm.
Medically accurate illustration of kidney cancer | Image Credit: © Crystal light - stock.adobe.com
June 1st 2025

Adjuvant pembrolizumab continues to show DFS, OS benefits for ccRCC at 5-year assessment

Silas Inman
"These long-term results continue to support [pembrolizumab's] use as a standard of care for patients at increased risk of recurrence," says Naomi B. Haas, MD.
Subcutaneous nivolumab approved in EU, Canada for solid tumors
May 28th 2025

Subcutaneous nivolumab approved in EU, Canada for solid tumors

Hannah Clarke
The approvals are supported by findings from the phase 3 CheckMate-67T trial.
© 2025 MJH Life Sciences

All rights reserved.